{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:32:05Z","timestamp":1769445125172,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Astellas Pharma, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The symptom burden associated with advanced pancreatic cancer, such as metastatic pancreatic adenocarcinoma (mPC), reduces patients\u2019 health-related quality of life (HRQoL). Recognizing the impact of disease- and treatment-related symptoms is essential in refining patient-reported outcomes (PROs) in clinical research, ensuring that PRO measures in clinical trials support US Food and Drug Administration label statements, and improving patient HRQoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with mPC and caregivers of patients with mPC were interviewed for this qualitative study. Insights from interviews were used to update a preliminary conceptual model derived from a targeted literature review. The primary objective was to obtain an in-depth understanding of patients\u2019 experience of living with mPC and the impact of mPC on patients\u2019 lives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across 19 interviews (n\u2009=\u200916 patients, n\u2009=\u20093 caregivers), the most frequently reported symptoms were tiredness (n\u2009=\u200919); fatigue, nausea, and weight loss (n\u2009=\u200918 each); and diarrhea and hair loss\/thinning (n\u2009=\u200916 each); 17 participants reported mPC- and\/or treatment-related pain. The most frequently reported impacts were anxiety (n\u2009=\u200917), reduced physical functioning (n\u2009=\u200916), and worry\/fear of disease (n\u2009=\u200916). After identification of the most salient symptoms and impacts, two symptoms and four impacts were added to the preliminary conceptual model and 31 symptoms and 11 impacts were removed to generate the final conceptual model (40 symptoms and 26 impacts).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This qualitative interview study uncovered previously unreported symptoms and impacts of mPC and supports the careful selection of appropriate PRO measures that more comprehensively reflect the experience of patients with mPC in future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf427","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T12:56:55Z","timestamp":1766235415000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study"],"prefix":"10.1093","volume":"31","author":[{"given":"Mok","family":"Oh","sequence":"first","affiliation":[{"name":"Astellas Pharma Global Development, Inc. , Northbrook, IL 60062,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-2120","authenticated-orcid":false,"given":"Lawrence","family":"Chang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc. , Northbrook, IL 60062,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Matney","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc. , Northbrook, IL 60062,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-9302","authenticated-orcid":false,"given":"Rupali","family":"Fuldeore","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc. , Northbrook, IL 60062,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6972-7802","authenticated-orcid":false,"given":"Eyra","family":"Perez","sequence":"additional","affiliation":[{"name":"IQVIA , Mexico City 03810,","place":["Mexico"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-4885","authenticated-orcid":false,"given":"Yesne","family":"Alici","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]},{"name":"Weill Cornell Medical College , New York, NY 10065,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1839-3047","authenticated-orcid":false,"given":"Joanne","family":"Buzaglo","sequence":"additional","affiliation":[{"name":"IQVIA , Plymouth Meeting, PA 19462,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6219-8982","authenticated-orcid":false,"given":"Michelle","family":"Mao","sequence":"additional","affiliation":[{"name":"IQVIA , Durham, NC 27703,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-3102","authenticated-orcid":false,"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College , New York, NY 10065,","place":["United States"]},{"name":"Department of Medicine, Gastrointestinal Oncology Service, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"2026012601214586800_oyaf427-B1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026012601214586800_oyaf427-B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"2026012601214586800_oyaf427-B3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2026012601214586800_oyaf427-B4","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2147\/CMAR.S376261","article-title":"Health-related quality of life of patients with metastatic pancreatic cancer: a systematic literature review","volume":"14","author":"Yoo","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2026012601214586800_oyaf427-B5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jval.2018.09.2842","article-title":"A review of patient-reported outcomes labeling for oncology drugs approved by the FDA and the EMA (2012-2016)","volume":"22","author":"Gnanasakthy","year":"2019","journal-title":"Value Health"},{"key":"2026012601214586800_oyaf427-B6","author":"US Food and Drug Administration"},{"key":"2026012601214586800_oyaf427-B7","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0959-8049(00)00186-6","article-title":"A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients","volume":"36","author":"Bjordal","year":"2000","journal-title":"Eur J Cancer"},{"key":"2026012601214586800_oyaf427-B8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0959-8049(99)00047-7","article-title":"Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer","volume":"35","author":"Fitzsimmons","year":"1999","journal-title":"Eur J Cancer"},{"key":"2026012601214586800_oyaf427-B9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2022.10.026","article-title":"Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer","volume":"178","author":"Cocks","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026012601214586800_oyaf427-B10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/14737167.2023.2263166","article-title":"Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies\u2013can alignment be improved?","volume":"24","author":"Wolters","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2026012601214586800_oyaf427-B11","author":"Australian Government Department of Health, Disability and Ageing"},{"key":"2026012601214586800_oyaf427-B12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"2026012601214586800_oyaf427-B13","author":"US Food and Drug Administration"},{"key":"2026012601214586800_oyaf427-B14","author":"US Food and Drug Administration"},{"key":"2026012601214586800_oyaf427-B15","first-page":"20","volume-title":"Using Patient Experience Data to Evaluate Medical Interventions: Generating, Understanding and Using Patient Experience Data Within and Alongside Clinical Trials","author":"Krupnick","year":"2023"},{"key":"2026012601214586800_oyaf427-B16","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.34193","article-title":"Cancer-related inflammation and depressive symptoms: systematic review and meta-analysis","volume":"128","author":"McFarland","year":"2022","journal-title":"Cancer"},{"key":"2026012601214586800_oyaf427-B17","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/jamaoncol.2016.0483","article-title":"Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort study in Sweden","volume":"2","author":"Lu","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026012601214586800_oyaf427-B18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000367913","article-title":"Mood and anxiety disorders as early manifestations of medical illness: a systematic review","volume":"84","author":"Cosci","year":"2015","journal-title":"Psychother Psychosom"},{"key":"2026012601214586800_oyaf427-B19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0885-3924(91)90027-2","article-title":"Symptoms of pancreatic cancer","volume":"6","author":"Krech","year":"1991","journal-title":"J Pain Symptom Manage"},{"key":"2026012601214586800_oyaf427-B20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2468-1253(16)30079-6","article-title":"Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study","volume":"1","author":"Walter","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026012601214586800_oyaf427-B21","doi-asserted-by":"crossref","first-page":"e70135","DOI":"10.1002\/pon.70135","article-title":"Pancreatic cancer patients supportive care needs: a qualitative analysis","volume":"34","author":"Fleszar-Pavlovic","year":"2025","journal-title":"Psychooncology"},{"key":"2026012601214586800_oyaf427-B22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1054\/bjoc.2001.1724","article-title":"Psychiatric morbidity and its recognition by doctors in patients with cancer","volume":"84","author":"Fallowfield","year":"2001","journal-title":"Br J Cancer"},{"key":"2026012601214586800_oyaf427-B23","doi-asserted-by":"crossref","first-page":"253s","DOI":"10.1200\/JCO.2003.09.133","article-title":"American Cancer Society Award lecture. Psychological care of patients: psycho-oncology\u2019s contribution","volume":"21","author":"Holland","year":"2003","journal-title":"J Clin Oncol"},{"key":"2026012601214586800_oyaf427-B24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.2022.40.4_suppl.534","article-title":"Patient-reported outcomes (PROs) in pancreatic cancer clinical trials (CTs) [abstract]","volume":"40","author":"Grewal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026012601214586800_oyaf427-B25","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.3390\/cancers12092487","article-title":"Patient-reported outcome measures in pancreatic cancer receiving radiotherapy","volume":"12","author":"Kouzy","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026012601214586800_oyaf427-B26","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1200\/JCO.2002.07.093","article-title":"Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy\u2013hepatobiliary questionnaire","volume":"20","author":"Heffernan","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026012601214586800_oyaf427-B27","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s11136-019-02233-6","article-title":"Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment","volume":"28","author":"Herman","year":"2019","journal-title":"Qual Life Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf427\/66107669\/oyaf427.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf427\/66107669\/oyaf427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/2\/oyaf427\/66107669\/oyaf427.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T06:21:57Z","timestamp":1769408517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf427\/8402145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf427","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,22]]},"article-number":"oyaf427"}}